Lanreotide Sun

Lanreotide, the active ingredient in Lanreotide Sun, is a synthetic somatostatin analog presented as a sterile injectable solution for subcutaneous administration. It is indicated for the long‑term control of growth hormone excess in acromegaly and for symptom management of carcinoid syndrome associated with neuroendocrine tumors in adult patients.

GNH USA supplies Lanreotide Sun as a licensed, GDP‑compliant international pharmaceutical product, providing reliable sourcing to hospitals, oncology centres, transplant units and community pharmacies worldwide, with support for regulatory documentation and cold‑chain logistics where required.

Lanreotide is used to modulate hormonal hypersecretion in disorders related to the somatostatin pathway. Acromegaly: reduces excess growth hormone secretion and normalizes IGF‑1 levels. Carcinoid syndrome (associated with neuroendocrine tumors): decreases flushing, abdominal pain and diarrhea by suppressing serotonin and other vasoactive peptides. Hormone‑secreting neuroendocrine tumors: controls tumor‑related peptide secretion and may contribute to disease stabilization.

Lanreotide may be associated with a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Injection site reactions: pain, erythema or induration. - Gastrointestinal disturbances: nausea, abdominal pain or diarrhea. - Hyperglycemia: increased blood glucose levels.

Serious or Rare Side Effects: - Gallbladder disease: cholelithiasis or biliary colic. - Pancreatitis: inflammation of the pancreas with severe abdominal pain. - Severe hypersensitivity: anaphylactic reactions or angioedema.

When prescribing Lanreotide, clinicians should consider several precautionary measures to ensure safe use. - Assess baseline hormone levels: measure GH and IGF‑1 before initiating therapy. - Monitor glucose: regular blood glucose testing in diabetic or pre‑diabetic patients. - Evaluate gallbladder status: perform ultrasound if history of gallstones. - Watch for pancreatitis signs: educate patients on abdominal pain and vomiting. - Adjust in renal/hepatic impairment: use caution and consider dose modification. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Cytochrome P450 inducers: may reduce lanreotide exposure; avoid concomitant use. - Somatostatin analog antagonists: can diminish therapeutic effect; avoid combination.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: lanreotide may increase glucose; monitor glycemic control. - Oral contraceptives: possible reduced hormone levels; observe for breakthrough bleeding. - QT‑prolonging drugs: monitor cardiac rhythm if combined.